Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001022372 | SCV001184101 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-03-26 | criteria provided, single submitter | clinical testing | The p.V146F variant (also known as c.436G>T), located in coding exon 4 of the RAD50 gene, results from a G to T substitution at nucleotide position 436. The valine at codon 146 is replaced by phenylalanine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Invitae | RCV001022372 | SCV002292347 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-01-15 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with RAD50-related conditions. ClinVar contains an entry for this variant (Variation ID: 824835). This variant is present in population databases (rs778914163, ExAC 0.001%). This sequence change replaces valine with phenylalanine at codon 146 of the RAD50 protein (p.Val146Phe). The valine residue is highly conserved and there is a small physicochemical difference between valine and phenylalanine. |